Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Diarrhea after fecal microbiota transplantation for recurrent Clostridioides difficile infection.

Krensky C, Poutanen SM, Hota SS.

CMAJ. 2019 May 21;191(20):E559-E561. doi: 10.1503/cmaj.181193. No abstract available.

PMID:
31113785
2.

Emerging antimicrobial resistance among Escherichia coli strains in bloodstream infections in Toronto, 2006-2016: a retrospective cohort study.

Mineau S, Kozak R, Kissoon M, Paterson A, Oppedisano A, Douri F, Gogan K, Willey BM, McGeer A, Poutanen SM.

CMAJ Open. 2018 Dec 3;6(4):E580-E586. doi: 10.9778/cmajo.20180039. Print 2018 Oct-Dec.

3.

Long-Term Effects of Phased Implementation of Antimicrobial Stewardship in Academic ICUs: 2007-2015.

Morris AM, Bai A, Burry L, Dresser LD, Ferguson ND, Lapinsky SE, Lazar NM, McIntyre M, Matelski J, Minnema B, Mok K, Nelson S, Poutanen SM, Singh JM, So M, Steinberg M, Bell CM.

Crit Care Med. 2019 Feb;47(2):159-166. doi: 10.1097/CCM.0000000000003514.

PMID:
30407951
4.

Emergence of Carbapenemase-Producing Enterobacteriaceae, South-Central Ontario, Canada1.

Kohler PP, Melano RG, Patel SN, Shafinaz S, Faheem A, Coleman BL, Green K, Armstrong I, Almohri H, Borgia S, Borgundvaag E, Johnstone J, Katz K, Lam F, Muller MP, Powis J, Poutanen SM, Richardson D, Rebbapragada A, Sarabia A, Simor A, McGeer A; Toronto Invasive Bacterial Diseases Network (TIBDN).

Emerg Infect Dis. 2018 Sep;24(9):1674-1682. doi: 10.3201/eid2409.180164.

5.

Fecal microbiota transplantation for recurrent Clostridium difficile infection.

Hota SS, Poutanen SM.

CMAJ. 2018 Jun 18;190(24):E746. doi: 10.1503/cmaj.171454. No abstract available.

6.

Regional variability in fecal microbiota transplantation practices: a survey of the Southern Ontario Fecal Microbiota Transplantation Movement.

Hota SS, Surangiwala S, Paterson AS, Coburn B, Poutanen SM; Southern Ontario Fecal Microbiota Transplantation (SOFT) Movement*.

CMAJ Open. 2018 Apr 18;6(2):E184-E190. doi: 10.9778/cmajo.20170109.

7.

Is a Single Fecal Microbiota Transplant a Promising Treatment for Recurrent Clostridium difficile Infection?

Hota SS, Poutanen SM.

Open Forum Infect Dis. 2018 Feb 23;5(3):ofy045. doi: 10.1093/ofid/ofy045. eCollection 2018 Mar.

8.

Reply to Galperine et al and Jansen.

Hota SS, Tomlinson G, Poutanen SM.

Clin Infect Dis. 2017 May 1;64(9):1293-1295. doi: 10.1093/cid/cix094. No abstract available.

PMID:
28158498
9.

Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015).

Walkty A, Karlowsky JA, Adam HJ, Lagacé-Wiens P, Baxter M, Mulvey MR, McCracken M, Poutanen SM, Roscoe D, Zhanel GG.

CMAJ Open. 2016 Oct 26;4(4):E641-E645. doi: 10.9778/cmajo.20160080. eCollection 2016 Oct-Dec.

10.

Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.

Hota SS, Sales V, Tomlinson G, Salpeter MJ, McGeer A, Coburn B, Guttman DS, Low DE, Poutanen SM.

Clin Infect Dis. 2017 Feb 1;64(3):265-271. doi: 10.1093/cid/ciw731. Epub 2016 Nov 9.

PMID:
28011612
11.

Evaluating Approaches for the Diagnosis of Hemodialysis Catheter-Related Bloodstream Infections.

Quittnat Pelletier F, Joarder M, Poutanen SM, Lok CE.

Clin J Am Soc Nephrol. 2016 May 6;11(5):847-54. doi: 10.2215/CJN.09110815. Epub 2016 Apr 1.

12.

Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.

Lapointe-Shaw L, Tran KL, Coyte PC, Hancock-Howard RL, Powis J, Poutanen SM, Hota S.

PLoS One. 2016 Feb 22;11(2):e0149521. doi: 10.1371/journal.pone.0149521. eCollection 2016.

13.

What Is the Appropriate Meropenem MIC for Screening of Carbapenemase-Producing Enterobacteriaceae in Low-Prevalence Settings?

Fattouh R, Tijet N, McGeer A, Poutanen SM, Melano RG, Patel SN.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1556-9. doi: 10.1128/AAC.02304-15.

14.

A case of rabies encephalitis: new dog, old tricks.

Wilcox ME, Poutanen SM, Krajden S, Agid R, Kiehl TR, Tang-Wai DF.

Neurology. 2014 Mar 25;82(12):1101. doi: 10.1212/WNL.0000000000000249. No abstract available.

15.

Reducing antimicrobial therapy for asymptomatic bacteriuria among noncatheterized inpatients: a proof-of-concept study.

Leis JA, Rebick GW, Daneman N, Gold WL, Poutanen SM, Lo P, Larocque M, Shojania KG, McGeer A.

Clin Infect Dis. 2014 Apr;58(7):980-3. doi: 10.1093/cid/ciu010. Epub 2014 Feb 26.

PMID:
24577290
16.

Vancomycin-variable Enterococcus faecium: in vivo emergence of vancomycin resistance in a vancomycin-susceptible isolate.

Coburn B, Low DE, Patel SN, Poutanen SM, Shahinas D, Eshaghi A, Willey BM, McGeer A.

J Clin Microbiol. 2014 May;52(5):1766-7. doi: 10.1128/JCM.03579-13. Epub 2014 Feb 12.

17.

Pleurostomophora richardsiae - an insidious fungus presenting in a man 44 years after initial inoculation: A case report and review of the literature.

Levenstadt JS, Poutanen SM, Mohan S, Zhang S, Silverman M.

Can J Infect Dis Med Microbiol. 2012 Fall;23(3):110-3. No abstract available.

18.

Indeterminate tcdB using a Clostridium difficile PCR assay: a retrospective cohort study.

Leis JA, Gold WL, Ng J, Hirji Z, Pillai DR, Broukhanski G, Raggiunti P, Hota S, McGeer A, Poutanen SM.

BMC Infect Dis. 2013 Jul 16;13:324. doi: 10.1186/1471-2334-13-324.

19.

Use of MALDI-TOF for diagnosis of microbial infections.

Bailey D, Diamandis EP, Greub G, Poutanen SM, Christensen JJ, Kostrzew M.

Clin Chem. 2013 Oct;59(10):1435-41. doi: 10.1373/clinchem.2013.204644. Epub 2013 May 21. No abstract available.

20.

Carbapenem-hydrolyzing oxacillinase-48 and oxacillinase-181 in Canada, 2011.

Mataseje LF, Boyd DA, Hoang L, Imperial M, Lefebvre B, Miller M, Poutanen SM, Roscoe D, Willey BM, Mulvey MR.

Emerg Infect Dis. 2013 Jan;19(1):157-60. doi: 10.3201/eid1901.120706. No abstract available.

21.

Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata.

Singh-Babak SD, Babak T, Diezmann S, Hill JA, Xie JL, Chen YL, Poutanen SM, Rennie RP, Heitman J, Cowen LE.

PLoS Pathog. 2012;8(5):e1002718. doi: 10.1371/journal.ppat.1002718. Epub 2012 May 17.

22.

The utility of prolonged culture of peritoneal dialysis effluent in the diagnosis and management of peritonitis.

Siccion Z, Poutanen SM, Perl J, Bargman JM.

Adv Perit Dial. 2011;27:43-4.

PMID:
22073827
23.

New Delhi metallo-β-lactamase-1: local acquisition in Ontario, Canada, and challenges in detection.

Kus JV, Tadros M, Simor A, Low DE, McGeer AJ, Willey BM, Larocque C, Pike K, Edwards IA, Dedier H, Melano R, Boyd DA, Mulvey MR, Louie L, Okeahialam C, Bayley M, Whitehead C, Richardson D, Carr L, Jinnah F, Poutanen SM.

CMAJ. 2011 Aug 9;183(11):1257-61. doi: 10.1503/cmaj.110477. Epub 2011 May 30.

24.

Plasmid comparison and molecular analysis of Klebsiella pneumoniae harbouring bla(KPC) from New York City and Toronto.

Mataseje LF, Boyd DA, Willey BM, Prayitno N, Kreiswirth N, Gelosia A, Poutanen SM, Low DE, Jenkins SG, Katz K, Mulvey MR.

J Antimicrob Chemother. 2011 Jun;66(6):1273-7. doi: 10.1093/jac/dkr092. Epub 2011 Mar 15.

PMID:
21406433
25.

In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.

Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):342-7. doi: 10.1016/j.diagmicrobio.2010.10.031.

PMID:
21353963
26.

Development of a molecular-beacon-based multi-allelic real-time RT-PCR assay for the detection of human coronavirus causing severe acute respiratory syndrome (SARS-CoV): a general methodology for detecting rapidly mutating viruses.

Hadjinicolaou AV, Farcas GA, Demetriou VL, Mazzulli T, Poutanen SM, Willey BM, Low DE, Butany J, Asa SL, Kain KC, Kostrikis LG.

Arch Virol. 2011 Apr;156(4):671-80. doi: 10.1007/s00705-010-0906-7. Epub 2011 Jan 11.

PMID:
21221674
27.

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS.

Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, Butany J.

Eur J Clin Invest. 2009 Jul;39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x. Epub 2009 May 6.

PMID:
19453650
28.

A new twist on an old problem. A case of pediatric meningitis caused by multidrug-resistant Streptococcus pneumoniae serotype 19 A.

Ciccotelli WA, Poutanen SM, Alqahtani M, Morris SK, Cox P, Low DE, Pillai DR, Opavsky MA.

Pediatr Infect Dis J. 2009 Jan;28(1):74-5. doi: 10.1097/INF.0b013e31818bfeb4. No abstract available.

PMID:
19057453
29.
30.

Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome.

Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, Muller MP, Gold WL, Richardson SE, Poutanen SM, Willey BM, DeVries ME, Fang Y, Seneviratne C, Bosinger SE, Persad D, Wilkinson P, Greller LD, Somogyi R, Humar A, Keshavjee S, Louie M, Loeb MB, Brunton J, McGeer AJ; Canadian SARS Research Network, Kelvin DJ.

J Virol. 2007 Aug;81(16):8692-706. Epub 2007 May 30.

31.

Do your biohazard, bioterror, and emergency planning NOW.

Poutanen SM.

MLO Med Lab Obs. 2007 Feb;39(2):38, 40-1. No abstract available.

PMID:
17375845
32.

Bilateral simultaneous Achromobacter xylosoxidans keratitis following penetrating keratoplasty.

Srinivasan S, McAllum P, Poutanen SM, Slomovic AR.

J Cataract Refract Surg. 2006 Dec;32(12):2149-52.

PMID:
17138001
33.

Disseminated phaeohyphomycosis due to Ochroconis gallopavum in the setting of advanced HIV infection.

Boggild AK, Poutanen SM, Mohan S, Ostrowski MA.

Med Mycol. 2006 Dec;44(8):777-82. Review.

PMID:
17127636
34.

Decreased prevalence of virulence factors among ciprofloxacin-resistant uropathogenic Escherichia coli isolates.

Drews SJ, Poutanen SM, Mazzulli T, McGeer AJ, Sarabia A, Pong-Porter S, Rzayev Y, Willey B, Green K, Low DE.

J Clin Microbiol. 2005 Aug;43(8):4218-20.

35.

Treatment and vaccines for severe acute respiratory syndrome.

Groneberg DA, Poutanen SM, Low DE, Lode H, Welte T, Zabel P.

Lancet Infect Dis. 2005 Mar;5(3):147-55. Review.

PMID:
15766649
36.

Nosocomial acquisition of methicillin-resistant Staphylococcus aureus during an outbreak of severe acute respiratory syndrome.

Poutanen SM, Vearncombe M, McGeer AJ, Gardam M, Large G, Simor AE.

Infect Control Hosp Epidemiol. 2005 Feb;26(2):134-7.

PMID:
15756882
37.

Proteomics and severe acute respiratory syndrome (SARS): emerging technology meets emerging pathogen.

Mazzulli T, Low DE, Poutanen SM.

Clin Chem. 2005 Jan;51(1):6-7. No abstract available.

38.

Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus.

Farcas GA, Poutanen SM, Mazzulli T, Willey BM, Butany J, Asa SL, Faure P, Akhavan P, Low DE, Kain KC.

J Infect Dis. 2005 Jan 15;191(2):193-7. Epub 2004 Dec 10.

PMID:
15609228
39.

Pulmonary pathology of severe acute respiratory syndrome in Toronto.

Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J.

Mod Pathol. 2005 Jan;18(1):1-10.

40.

Severe acute respiratory syndrome: an update.

Poutanen SM, Low DE.

Curr Opin Infect Dis. 2004 Aug;17(4):287-94. Review.

PMID:
15241071
41.

Clostridium difficile-associated diarrhea in adults.

Poutanen SM, Simor AE.

CMAJ. 2004 Jul 6;171(1):51-8. Review.

42.

Severe acute respiratory syndrome.

Christian MD, Poutanen SM, Loutfy MR, Muller MP, Low DE.

Clin Infect Dis. 2004 May 15;38(10):1420-7. Epub 2004 Apr 29. Review.

PMID:
15156481
43.

Transmission and Control of SARS.

Poutanen SM, McGeer AJ.

Curr Infect Dis Rep. 2004 Jun;6(3):220-227.

PMID:
15142486
44.

Severe acute respiratory syndrome-associated coronavirus in lung tissue.

Mazzulli T, Farcas GA, Poutanen SM, Willey BM, Low DE, Butany J, Asa SL, Kain KC.

Emerg Infect Dis. 2004 Jan;10(1):20-4.

45.

Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience.

Tang P, Louie M, Richardson SE, Smieja M, Simor AE, Jamieson F, Fearon M, Poutanen SM, Mazzulli T, Tellier R, Mahony J, Loeb M, Petrich A, Chernesky M, McGeer A, Low DE, Phillips E, Jones S, Bastien N, Li Y, Dick D, Grolla A, Fernando L, Booth TF, Henry B, Rachlis AR, Matukas LM, Rose DB, Lovinsky R, Walmsley S, Gold WL, Krajden S; Ontario Laboratory Working Group for the Rapid Diagnosis of Emerging Infections.

CMAJ. 2004 Jan 6;170(1):47-54.

46.

Illness in intensive care staff after brief exposure to severe acute respiratory syndrome.

Scales DC, Green K, Chan AK, Poutanen SM, Foster D, Nowak K, Raboud JM, Saskin R, Lapinsky SE, Stewart TE.

Emerg Infect Dis. 2003 Oct;9(10):1205-10. No abstract available.

47.

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P, Ephtimios IE, Kitai I, Mederski BD, Shadowitz SB, Gold WL, Hawryluck LA, Rea E, Chenkin JS, Cescon DW, Poutanen SM, Detsky AS.

JAMA. 2003 Jun 4;289(21):2801-9. Epub 2003 May 6. Erratum in: JAMA. 2003 Jul 16;290(3):334.

PMID:
12734147
48.

Identification of severe acute respiratory syndrome in Canada.

Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, Tellier R, Draker R, Adachi D, Ayers M, Chan AK, Skowronski DM, Salit I, Simor AE, Slutsky AS, Doyle PW, Krajden M, Petric M, Brunham RC, McGeer AJ; National Microbiology Laboratory, Canada; Canadian Severe Acute Respiratory Syndrome Study Team.

N Engl J Med. 2003 May 15;348(20):1995-2005. Epub 2003 Mar 31.

49.

Molecular characterization of multidrug resistance in Streptococcus mitis.

Poutanen SM, de Azavedo J, Willey BM, Low DE, MacDonald KS.

Antimicrob Agents Chemother. 1999 Jun;43(6):1505-7.

50.

Risk factors, clinical features and outcome of Acinetobacter bacteremia in adults.

Poutanen SM, Louie M, Simor AE.

Eur J Clin Microbiol Infect Dis. 1997 Oct;16(10):737-40.

PMID:
9405943

Supplemental Content

Loading ...
Support Center